Elizabeth K. Lee Md

This study tests two drugs, pembrolizumab and lenvatinib, in 30 people with recurrent clear cell ovarian cancer. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants must have had at least one prior treatment and have measurable disease.